Payment overview · 2025
General Payments
$453.46
22 reported records · 9 companies
Healthcare provider profile · identity verified
Xiaobin Li, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAVERTOWN, PA · NPI 1346225034
Verified facts
What the public records show
CMS Open Payments records show Xiaobin Li, M.D. received $453.46 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $171.51 | 37.8% | 13 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $125.00 | 27.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.83 | 7.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.46 | 6.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.21 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.17 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.66 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.52 | 3.9% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $16.10 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $453.46 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $125.71 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $125.71 | 9 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.80 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 129 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
129 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 33 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 165 |
| Vascepa | Icosapent Ethyl | 269 | 99 |
| Losartan Potassium | Losartan Potassium | 267 | 105 |
| Metformin Hcl | Metformin Hcl | 253 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 109 |
| Famotidine | Famotidine | 173 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 63 |
| Gabapentin | Gabapentin | 137 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 52 |
| Omeprazole | Omeprazole | 132 | 51 |
| Creon | Lipase/Protease/Amylase | 129 | 46 |
| Alendronate Sodium | Alendronate Sodium | 126 | 52 |
| Montelukast Sodium | Montelukast Sodium | 114 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 60 |
| Lisinopril | Lisinopril | 102 | 42 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 96 | 96 |
| Finasteride | Finasteride | 94 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 31 |
| Jardiance | Empagliflozin | 88 | 25 |
| Celecoxib | Celecoxib | 86 | 45 |
| Azithromycin | Azithromycin | 84 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 26 |
| Simvastatin | Simvastatin | 78 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 40 |
| Eliquis | Apixaban | 69 | 21 |
| Linzess | Linaclotide | 69 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 33 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 66 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 29 |
| Januvia | Sitagliptin Phosphate | 64 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 37 |
| Furosemide | Furosemide | 59 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 23 |
| Meclizine Hcl | Meclizine Hcl | 49 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | 20 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 46 | 27 |
| Trulicity | Dulaglutide | 46 | 12 |
| Donepezil Hcl | Donepezil Hcl | 45 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 33 |
| Zenpep | Lipase/Protease/Amylase | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 16 |
| Valacyclovir | Valacyclovir Hcl | 38 | 25 |
| Amoxicillin | Amoxicillin | 37 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 22 |
| Allopurinol | Allopurinol | 35 | 17 |
| Carvedilol | Carvedilol | 32 | 15 |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Tradjenta | Linagliptin | 31 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 15 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Prolia | Denosumab | 29 | 19 |
| Glipizide | Glipizide | 28 | 12 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 12 |
| Trazodone Hcl | Trazodone Hcl | 27 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 22 |
| Ketoconazole | Ketoconazole | 25 | 14 |
| Ciclopirox | Ciclopirox | 24 | 14 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 18 |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 13 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Prednisone | Prednisone | 16 | 14 |
| Acarbose | Acarbose | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Asenapine Maleate | Asenapine Maleate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.46 · 22 records | ABBVIE INC. | CREON, Cologuard Collection Kit, EVENITY, GIMOTI, LINZESS, MOUNJARO, VOQUEZNA, VRAYLAR, Vemlidy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error